Anthony S. Wierzbicki
Anthony S. Wierzbicki
Consultant (Honorary Professor) in Metabolic Medicine, Guy's & St Thomas' Hospitals London UK
Dirección de correo verificada de kcl.ac.uk
Título
Citado por
Citado por
Año
The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association
SS Gidding, M Ann Champagne, SD de Ferranti, J Defesche, MK Ito, ...
Circulation 132 (22), 2167-2192, 2015
4032015
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
GF Watts, S Gidding, AS Wierzbicki, PP Toth, R Alonso, WV Brown, ...
International journal of cardiology 171 (3), 309-325, 2014
4012014
Homocysteine and cardiovascular disease: a review of the evidence
AS Wierzbicki
Diabetes and Vascular Disease Research 4 (2), 143-149, 2007
3472007
The lipid and non-lipid effects of statins
AS Wierzbicki, R Poston, A Ferro
Pharmacology & therapeutics 99 (1), 95-112, 2003
3172003
“European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses
D P Mikhailidis, M Elisaf, M Rizzo, K Berneis, B Griffin, A Zambon, ...
Current vascular pharmacology 9 (5), 533-571, 2011
2732011
Familial hypercholesterolaemia: summary of NICE guidance
AS Wierzbicki, SE Humphries, R Minhas
Bmj 337, 2008
2652008
Familial hypercholesterolaemia
JC Defesche, SS Gidding, M Harada-Shiba, RA Hegele, RD Santos, ...
Nature reviews Disease primers 3 (1), 1-20, 2017
2592017
Relation of erectile dysfunction to angiographic coronary artery disease
H Solomon, JW Man, AS Wierzbicki, G Jackson
The American journal of cardiology 91 (2), 230-231, 2003
2582003
Multiple actions of high-density lipoprotein
M Florentin, EN Liberopoulos, AS Wierzbicki, DP Mikhailidis
Current opinion in cardiology 23 (4), 370-378, 2008
2452008
Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection
ER Pearson, S Pruhova, CJ Tack, A Johansen, HAJ Castleden, PJ Lumb, ...
Diabetologia 48 (5), 878-885, 2005
2412005
Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
S Rabar, M Harker, N O’Flynn, AS Wierzbicki
Bmj 349, g4356, 2014
2362014
Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial
T Marteau, V Senior, SE Humphries, M Bobrow, T Cranston, MA Crook, ...
American journal of medical genetics Part A 128 (3), 285-293, 2004
1972004
Statin-fibrate combination therapy for hyperlipidaemia: a review
AS Wierzbicki, DP Mikhailidis, R Wray, M Schachter, R Cramb, ...
Current medical research and opinion 19 (3), 155-168, 2003
1942003
Refsum's disease: a peroxisomal disorder affecting phytanic acid α‐oxidation
AS Wierzbicki, MD Lloyd, CJ Schofield, MD Feher, FB Gibberd
Journal of neurochemistry 80 (5), 727-735, 2002
1812002
Identification of PEX7 as the second gene involved in Refsum disease
DM Van Den Brink, P Brites, J Haasjes, AS Wierzbicki, J Mitchell, ...
The American Journal of Human Genetics 72 (2), 471-477, 2003
1612003
Polymorphisms in the P450 c17 (17-hydroxylase/17, 20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in …
J Somner, S McLellan, J Cheung, YT Mak, ML Frost, KM Knapp, ...
The Journal of Clinical Endocrinology & Metabolism 89 (1), 344-351, 2004
1382004
α‐Methylacyl‐CoA racemase–an ‘obscure’metabolic enzyme takes centre stage
MD Lloyd, DJ Darley, AS Wierzbicki, MD Threadgill
The FEBS Journal 275 (6), 1089-1102, 2008
1302008
Effect of atorvastatin on plasma fibrinogen.
AS Wierzbicki, PJ Lumb, YK Semra, MA Crook
Lancet (London, England) 351 (9102), 569, 1998
1251998
Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation
GF Watts, S Gidding, AS Wierzbicki, PP Toth, R Alonso, WV Brown, ...
Journal of Clinical Lipidology 8 (2), 148-172, 2014
1212014
Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management
Scientific Steering Committee on behalf of the Simon Broome Register Group
Atherosclerosis 142 (1), 105-112, 1999
113*1999
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20